“Safeguarding Innovation: The Importance of a Sound AI Policy in Pharmaceutical Research and Development, Drug Discovery & Development”

From accelerating drug discovery and optimizing clinical trials to automating regulatory documentation and improving patient engagement, AI offers opportunities to improve efficiency, reduce costs, and bring therapies to market faster. In an article published by Drug Discovery & Development, Marshall Gerstein Partner and patent attorney Ryan Phelan offers guidance to pharmaceutical innovators on establishing sound and comprehensive AI policies as part of their R&D strategies.

“The sensitive nature of biomedical data, combined with strict intellectual property frameworks and regulatory standards, makes it essential that pharmaceutical companies adopt AI in a manner that protects both their scientific integrity and their business interests,” Phelan writes.

Read his advice on what a solid AI policy should capture in Drug Discovery & Development.